Verification of the Combimatrix influenza detection assay for the detection of influenza A subtype during the 2007–2008 influenza season in Toronto, Canada by Bolotin, Shelly et al.
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
Virology Journal
Open Access Short report
Verification of the Combimatrix influenza detection assay for the 
detection of influenza A subtype during the 2007–2008 influenza 
season in Toronto, Canada
Shelly Bolotin*1, Ernesto Lombos1, Rani Yeung1, AliReza Eshaghi1, 
Joanne Blair1 and Steven J Drews1,2,3
Address: 1Ontario Agency for Health Protection and Promotion, 81 Resources Road, Toronto, Ontario, M9P 3T1, Canada, 2Department of 
Microbiology, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada and 3Department of Laboratory Medicine and 
Pathobiology, University of Toronto, 100 College Street, Room 110, Toronto, Ontario, M5G 1L5, Canada
Email: Shelly Bolotin* - Shelly.bolotin@oahpp.ca; Ernesto Lombos - Ernesto.lombos@oahpp.ca; Rani Yeung - rani.yeung@gmail.com; 
AliReza Eshaghi - alireza.eshaghi@oahpp.ca; Joanne Blair - joanne.blair@oahpp.ca; Steven J Drews - steven.drews@oahpp.ca
* Corresponding author    
Abstract
The increase in adamantine resistance in influenza A (H3N2) and the emergence of oseltamivir
resistance in influenza A (H1N1) has necessitated the use of rapid methodologies to detect
influenza subtype. The purpose of this study was to evaluate the CombiMatrix influenza detection
system compared to the FDA approved Luminex Respiratory virus panel (RVP) assay for influenza
A subtyping. Verification of the CombiMatrix influenza detection system was carried out using the
Luminex RVP assay as a reference method. A limit of detection (LOD) series was performed using
the Luminex and CombiMatrix systems with both influenza A H3N2 and H1N1 viruses. Seventy-
five clinical specimens were used in the study. Of these, 16 were influenza A (H3N2) positive and
five were influenza A (H1N1) positive. Fifty-four specimens were influenza A negative or "no call"
(inconclusive) or could not be subtyped. The LOD of the Luminex RVP assay was found to be 0.3
TCID50s/mL for influenza A (H3N2) and 16 TCID50s/mL for influenza A (H1N1). The LOD of the
CombiMatrix influenza detection system was 200 TCID50s/mL for influenza A (H3N2) and 16 000
TCID50s/mL for influenza A (H1N1). The sensitivity of the CombiMatrix influenza detection system
was 95.2% and the specificity was 100%. The CombiMatrix influenza detection system is an effective
methodology for influenza A subtype analysis, specifically in laboratories with a constrained budget
or limited molecular capabilities.
Findings
Classification of seasonal influenza A into H3N2 or H1N1
subtypes is an important step in the characterization of
circulating influenza A strains. The recent emergence of
adamantine resistance in influenza A (H3N2) [1] and
oseltamivir resistance in influenza A (H1N1) [2] has
necessitated the use of methodologies that allow for rapid
influenza sub-type analysis. A variety of both "home-
brew" and commercial molecular assays that allow for
sub-type analysis of influenza A subtypes are now availa-
ble. Although many laboratories utilize "home-brew"
subtyping methodologies [3,4], these are controversial
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due to multiple regulatory issues with the use of these
assays leading to a growing movement for the use of com-
mercial molecular diagnostics [5,6].
The purpose of this study was to evaluate the sensitivity
and specificity of the CombiMatrix influenza A detection
system for influenza A subtype analysis compared to the
Luminex RVP assay, an FDA approved Respiratory Virus
Panel (RVP) assay [7,8]. The CombiMatrix influenza A
detection system is a commercial multiplex reverse tran-
scriptase PCR (RT-PCR) assay and microarray detection
system that can be used to identify hemagglutinin (HA)
subtypes 1–16 and neuraminidase (NA) subtypes 1–9 [9].
Unlike conventional fluorescence-based microarrays, the
CombiMatrix is an electrochemical system that detects
current generated from redox enzymatic reactions (biotin-
streptavidin) when DNA-probe hybridization occurs [10].
Verification of this technology was performed using spec-
imens from Toronto, Canada collected during the 2007–
2008 influenza season.
Nasopharyngeal specimens from patients from Toronto,
Canada with influenza-like illness were sent to the Central
Branch of the Ontario Public Health Laboratories (CPHL)
during the 2007–2008 influenza season. Specimens were
collected using the flocculated Starswab® Multitrans Col-
lection and Transport system (Starplex, Bolton, Canada).
Total nucleic acid was extracted from each specimen using
the easyMag automated extraction system (bioMérieux,
Montreal, Canada) as per the manufacturer's protocols.
To control for extraction all specimens were tested for
human target gapdh by using the gapdh RT-PCR kit (ABI,
Foster City, CA) as per the manufacturer's instructions and
as previously described [11].
Seventy-five specimens submitted to CPHL were included
in this study (Table 1). Specimens were first screened by
the Luminex RVP assay (Luminex Molecular Diagnostics,
Toronto, Canada), a commercial FDA cleared assay that
detects multiple respiratory pathogens including influ-
enza A H3N2 and H1N1, influenza B, respiratory syncy-
tial virus A (RSV A), respiratory syncytial virus B (RSV B),
parainfluenza (PIV) 1, PIV2, PIV3, human rhinovirus A,
human metapneumovirus (HMPV) and adenovirus.
Nucleic acid from these specimens was then tested by the
CombiMatrix influenza A detection system (CombiMa-
trix, Mukilteo, WA) as per the manufacturers instructions
and as previously described [9]. RT-PCR reactions were
carried out using the iCycler PCR thermocycler (Bio-Rad,
Milpitas, CA). Influenza A subtyping steps were carried
out using CombiMatrix influenza A detection arrays in
conjunction with an Electrasense array reader as per the
manufacturer's instructions and as previously described
[9,10].
The limit of detection (LOD) for both the Luminex RVP
assay and the CombiMatrix influenza A detection system
was determined using serial ten-fold dilutions of nucleic
acid from influenza A/Brisbane/10/2007 (H3N2) virus
from a clinical specimen and influenza A/PR/8/34
(H1N1) virus (Advanced Biotechnologies Inc., Columbia,
MD) in PCR-grade water. The starting concentration of
H3N2 virus was 106.8 TCID50s/mL and the starting con-
centration of H1N1 virus was 109.5 TCID50s/mL. The LOD
was calculated using probit regression with a 95% confi-
dence interval (95% CI) using SPSS 15 (SPSS Inc., Chi-
cago, IL).
Of the 75 specimens characterized using the Luminex RVP
assay (Table 1), 21 were influenza A positive and were
subtyped by the Luminex RVP assay as either H3 (n = 16)
or H1 (n = 5). Fifty-four specimens were defined by the
Luminex RVP assay as both H3 and H1 "undetected". Of
these, one specimen was detected by the Luminex RVP
assay as influenza A but could not be typed and three
specimens were detected as influenza A "No-call". The
remaining 50 were identified as not influenza A by the
Luminex RVP assay with the following distribution: no
virus detected (17/50), influenza B (1/50), enterovirus/
rhinovirus (7/50), HMPV (6/50), PIV1 (4/50), PIV2 (2/
50), PIV3 (5/50), adenovirus (3/50), RSV A (2/50), mixed
adenovirus and enterovirus/rhinovirus (1/50), mixed ade-
novirus and RSV A (1/50), mixed PIV2 and enterovirus/
rhinovirus (1/50).
Compared to the Luminex RVP assay, the sensitivity of the
CombiMatrix influenza detection system for the detection
of an influenza A subtype (either H1 or H3) was 95.2%
(Table 1). All 16 specimens characterized as H3 by the
Luminex RVP assay were identified by the CombiMatrix
influenza detection system. Four of five specimens charac-
terized as H1 by the Luminex RVP assay were identified by
the CombiMatrix influenza detection system. The specifi-
Table 1: Sensitivity and specificity of the CombiMatrix influenza detection system
Luminex positive Luminex negative
CombiMatrix positive 20 0
CombiMatrix negative 15 4
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city of the CombiMatrix influenza detection system for
the detection of an influenza A subtype (either H1 or H3)
was 100%.
The LOD of the Luminex RVP assay was found to be 0.3
TCID50s/mL for influenza A (H3N2) and 16 TCID50s/mL
for influenza A (H1N1). The LOD of the CombiMatrix
influenza detection system was 200 TCID50s/mL for influ-
enza A (H3N2) and 16 000 TCID50s/mL for influenza A
(H1N1).
Subtype analysis of influenza A is becoming increasingly
prevalent in clinical microbiology laboratories, and is
essential for public health surveillance of circulating
strains, determination of annual vaccine mismatch and
therapeutic decision making with regards to antiviral
resistance.
Until recently, subtyping of influenza A was performed
using antigenic determination of culture-grown virus.
This method requires cell culture facilities and has a turn-
around-time (TAT) of up to 10 days. The development of
molecular methods for subtype determination has facili-
tated shorter TATs however the use of molecular technol-
ogy is still hampered by the expertise required to perform
the tests. This study evaluated the CombiMatrix influenza
detection system for subtype analysis, a molecular detec-
tion system that is easier to operate than conventional
real-time PCR instruments. This system was compared to
the FDA-approved Luminex RVP assay.
While the CombiMatrix influenza detection system
required less expertise to operate, its LOD was three logs
lower than the Luminex RVP assay. The LOD for H1N1
subtypes was particularly low (16 000 TCID50s/mL)
resulting in a negative result for one H1N1 isolate that was
successfully subtyped using the Luminex RVP assay. This
decreased sensitivity could be due to the inherent differ-
ences between the electrochemical CombiMatrix technol-
ogy compared to the bead-based fluorescence technology
of the Luminex platform, or as a result of differences in
PCR efficiencies between the two systems. Despite the dif-
ference in LOD, the sensitivity of the CombiMatrix system
was still high at 95.2%, making this instrument quite suit-
able as a secondary testing method.
In conclusion the CombiMatrix influenza detection sys-
tem is an effective method for influenza A subtype analy-
sis. Its ease of operation makes it suitable for laboratories
with a limited budget or limited molecular knowledge.
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